Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NRX Pharmaceuticals ( (NRXP) ) has issued an update.
On September 8, 2025, NRx Pharmaceuticals, through its subsidiary HOPE Therapeutics, completed the acquisition of Dura Medical, a Florida-based provider of interventional psychiatry services. This acquisition, along with pending ones, aims to expand HOPE’s network across Florida, integrating Dura’s expertise in treating severe depression and PTSD, particularly benefiting veterans. The move is part of HOPE’s strategy to build a nationwide network of clinics, enhancing its market position and service offerings.
The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is advancing products like NRX-100 and NRX-101, which have received designations for treating suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is building a network of interventional psychiatry clinics offering therapies such as ketamine and transcranial magnetic stimulation.
Average Trading Volume: 322,742
Technical Sentiment Signal: Buy
Current Market Cap: $68.46M
See more data about NRXP stock on TipRanks’ Stock Analysis page.